Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, ...

Speaker Julie Zickafoose left conference attendees with ideas to bring conservation to their world of bluebirding.

Bristol Myers Squibb Co.’s decision this week to snag Bluebird Bio Inc. spinout 2seventy Bio Inc. for $102 million net – just weeks after investors bid $30 million for Bluebird itself – seemed to ...

She is passionate about empowering others to protect life's most important assets. Wh... Tony Steuer, CLU, LA, CPFFE, is an internationally recognized financial preparedness advocate, podcaster ...

FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...

A woman who has taken over a cafe in a former coastguard station says she has to “pinch herself” every day at getting to work ...

“With the backing of Carlyle and SK Capital, we will bring the capital and commercial capabilities needed to accelerate and expand patient access to bluebird’s life-changing gene therapies.

A flock of cartoonish-looking bluebirds was set out on our dining room table. When family visited someone said, "What's up with the blue penguins?" ...

Bluebird’s lead CAR-T cancer cell therapy idecabtagene vicleucel (ide-cel) was last year hit with an FDA refuse-to-file letter, which required additional data on chemistry, manufacturing and ...

Naturalist and author Julie Zickafoose presented "Back to the Basics" at the 2025 Ohio Bluebird Society Conference. Zickafoose shared her experiences and observations from 40 years of studying ...

Carlyle (NASDAQ: CG) and SK Capital Partners will acquire bluebird bio (NASDAQ: BLUE), according to a news release. bluebird, ...